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Background. Ewing’s sarcoma of extraskeletal origin is uncommon and that is of primary renal origin in adults are rare. There
is no consensus on the optimal management of Ewing’s tumors of renal origin. Methods. A retrospective review of the clinical
features, treatment, and outcome of adult patients with primary renal extra-skeletal Ewing’s sarcoma who were treated at the Royal
MarsdenhospitalfromJanuary1993–December2007isreported.Results.SevenadultpatientswithprimaryrenalEwing’ssarcoma
were identiﬁed. All four patients with nonmetastatic disease had radical nephrectomy and received adjuvant chemotherapy +/−
radiotherapy. Two developed metastatic disease while on adjuvant chemotherapy, and one patient relapsed after 55 months. The
three patients with metastatic disease at presentation did not have nephrectomy and were treated with chemotherapy. All three
patients had disease progression with a dismal outcome. Only one patient in the whole group is alive and disease free. The median
overall survival was 62.8 months, and the median disease-free survival in patients with nonmetastatic disease after combined
modality treatment was 30.3 months. Conclusion. Primary adult renal Ewing’s sarcoma is an aggressive tumor with a propensity
for early metastasis. Radical nephrectomy with adjuvant combination chemotherapy produced the best results but the outlook
remained poor with only one patient experiencing long disease-free survival.
Copyright © 2009 Ravindra Mukkunda et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
1.Introduction
Ewing’s family of tumors, which include Ewing’s sarcoma of
bone, extraosseous Ewing’s, and primitive neuro-ectodermal
tumor (PNET), primarily arises in bones, most commonly
in children and young adults, and are extraosseous in
approximately 6% of cases [1, 2]. Most common sites for
extraosseousEwing’sarethetrunk,extremity,headandneck,
and retroperitoneum [1, 2]. Ewing’s sarcoma of primary
renal origin is a rare entity in the adult population and
often has an aggressive course [3–5]. The principles of
management of extraskeletal Ewing’s tumors have been
extrapolated from the experience of treating osseous Ewing’s
sarcoma or from high grade sarcomas of the same site and
stage, though some studies have suggested that extraosseous
Ewing’s sarcomas may have a poorer prognosis [2, 6].
Literature regarding primary renal Ewing’s sarcoma in adults
is limited to case reports or short case series, and no deﬁnite
recommendations regarding optimal treatment have been
deﬁned[5,7,8].Asingleinstitutionexperienceoftheclinical
presentation, management, and outcome of this rare tumor
is presented here together with areviewof relevant literature.
2. Methods
We conducted a retrospective review of the case records
of adult patients who had histologically proven Ewing’s
tumors of primary renal origin and who were treated at the
RoyalMarsdenHospitalfromJanuary1993–December2007.
Criteria for inclusion in the study were as follows.
(1) Primary renal tumors on computerised tomography
(CT).2 Sarcoma
(2) Histology showing a small round cell tumor with
morphology suggestive of Ewing’s family tumors, for
example, uniform cells with even chromatin pattern,
rosetteformation,andimmunohistochemistryshow-
ing CD99 positivity and absence of markers for other
small round cell tumors.
The standard patient evaluation consisted of history and
clinical examination, complete blood counts, biochemistry,
CTthorax,abdomenandpelvis,radionuclide bonescan,and
bone marrow biopsy. Histologically, tumors were assessed
morphologically and immunohistochemically with a panel
of markers including CD99 and neural markers such as
neuron speciﬁc enolase (NSE), synaptophysin, and S100
protein. Other malignant tumors in the diﬀerential diagnosis
wereruledoutusingfurthermarkers,includingcytokeratins,
epithelial membrane antigen, leucocyte common antigen,
desmin, and smooth muscle actin. Molecular studies were
conducted to look for characteristic translocations if samples
were available. The demographic proﬁle, clinical character-
istics, pathology, treatment, and outcome were analysed.
Disease-free survival and overall survival were calculated by
the Kaplan-Meier method, and the signiﬁcance of diﬀerences
between variables to predict for progression free and overall
survival were analysed by log-rank test, with a P value <.05
considered signiﬁcant. Univariate analysis of predictors of
survival was performed using the Cox proportional hazards
model. Statistical analysis was conducted with SPSS 14 (SPSS
Inc, Chicago, Ill, USA).
3. Results
The study population consisted of seven patients, four of
whom were male and three female. The median age was 43
years (range 25–57 years). The primary site of disease was
right kidney in two patients and left kidney in ﬁve patients
(Figure 1). Four patients presented with abdominal masses,
other presentations being, pedal oedema and hypertension,
back pain with hematuria, and varicocoele. CT showed
large renal masses in all patients, which were diagnosed as
possible primary renal tumor. Inferior venacaval inﬁltration
and thrombus were seen in two patients. Three patients were
found to have metastatic disease at presentation, the liver
being the site of secondaries in all three. The diagnosis was
made by biopsy in three patients and by nephrectomy in
four patients. Histopathologic examination showed tumors
composed of sheets, islands, and lobules of small round
cells with uniform round to ovoid vesicular nuclei and
scanty cytoplasm (Figure 2). Most tumors showed diﬀuse
membranous positivity for CD99, and three tumors showed
focal positivity for AE1/AE3. FISH analysis, using the Vysis
LSI EWSR1 dual colour break-apart rearrangement probe
for 22q12, showed EWS gene rearrangement in two of
three patients, while the presence of the EWS-FLI 1 fusion
transcript was detected by PCR in two of the three patients
in whom the test was performed.
4.Patients withNonmetastatic Disease
The four patients with nonmetastatic disease underwent
radical nephrectomy. One patient had a solitary pos-
itive perinephric node on lymph node dissection. All
four patients with nonmetastatic disease received adju-
vant chemotherapy. The ﬁrst patient had 4 cycles of
vincristine/ifosfamide/doxorubicin and 2 cycles of ifosfo-
mide/etoposide chemotherapy with a relapse free survival of
149 months.
The second patient received six cycles of adjuvant
chemotherapy comprising cyclophosphamide/doxorubi-
cin/vincristine alternating with cisplatin/etoposide. He
was disease-free for 55 months and then relapsed in the
lungs, for which he had a left lower lobectomy. This was
followed by adjuvant etoposide/vincristine/actinomycin
D—ifosfamide/doxorubicin. He relapsed again after 36
months with extensive pleural disease for which he received
radiotherapy of 30Gy in 20 fractions, and palliative
chemotherapy with etoposide/cisplatin, with progressive
disease.
The third patient developed liver metastasis soon after
nephrectomy, and received chemotherapy with VAC (vin-
cristine/actinomycin D/cyclophosphamide) and progressed
after one cycle with further intraabdominal disease. The
fourth patient received 4 cycles of accelerated MVAC
(methotrexate, vinblastine, doxorubicin/cisplatin) due to
an initial diagnosis of poorly diﬀerentiated transitional
cell carcinoma. Subsequently, following a revision of the
diagnosis to Ewing’s, he received 2 cycles of VIDE (vin-
cristine/ifosfamide/doxorubixin/etoposide) followed by 3
cycles without etoposide and with the addition of dexra-
zoxane in view of a fall in the cardiac ejection fraction.
Unfortunately, he progressed with the development of bone
metastases while on chemotherapy.
5. Patients withMetastaticDisease
The three patients with metastatic disease at presentation
did not have a nephrectomy and were treated initially with
chemotherapy. The ﬁrst patient received 6 courses of cis-
platin/doxorubicin alternating with ifosfamide/doxorubicin,
with a partial response. Progression in the liver occurred
after 24 months for which she received oral etoposide and
ifosfamide. The second patient received oral etoposide for
12 months and died of progressive disease. The third patient
received 1 cycle of vincristine/ifosfamide/etoposide followed
by 3 cycles of ifosfamide/doxorubicin/etoposide and then 6
cycles of VAC, but progressed after 12 months.
The patient with a positive lymph node received postop-
erativeradiotherapytotherenalbedandnodalregions,while
none of the other patients received adjuvant radiotherapy.
Palliative radiotherapy to metastatic sites was delivered as
indicated.
6. Outcome
The median follow-up was 36 (5–149) months. Only one
patient who had radical nephrectomy for nonmetastaticSarcoma 3
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Figure 1: Kaplan-Meier plot of overall survival in all patients.
disease and completed adjuvant chemotherapy is disease free
after 14 years. Median overall survival was 62.8 (6.5–149)
months. The 1-year, 3-year, and 5-year overall survivals were
85.7%, 64.3%, and 42.9%, respectively. The only signiﬁcant
predictor of prolonged survival on univariate analysis was
male sex (P = .04), while metastasis at diagnosis (P =
.38), complete surgery (P = .38), and disease relapse after
adjuvant chemotherapy (P = .25) were not statistically
signiﬁcant. Median disease-free survival in patients with
nonmetastatic disease was 30.35 (range from 5.1 to 149)
months.Nosigniﬁcantpredictorfordisease-freesurvivalwas
identiﬁed, due to low patient numbers. Of all the patients
in the study, 71.4% and 85.7% had progressive disease at
1 and 3 years, respectively. The median disease progression
free interval for all patients was 5.13 (0–149) months, the
signiﬁcant predictors on univariate analysis being metastasis
at diagnosis (P = .014) and complete surgery (P = .14),
w h i l em a l es e x( P = .23) was not signiﬁcant.
7. Discussion
The results from our series of seven adult patients with
primary renal Ewing’s sarcoma reveal a propensity for early
metastasis and an aggressive clinical course. In our patients,
a preoperative diagnosis was diﬃcult as the radiological
features were indistinguishable from primary renal cell
carcinoma or a transitional carcinoma of the renal pelvis.
The diagnosis of primary renal Ewing’s sarcoma is usually
made postoperatively and requires histological examination,
with a combination of immunohistochemical and molecular
ancillarytechniques[8,9].Onlightmicroscopytumorsshow
as m a l lr o u n dc e l lm o r p h o l o g y ,a n di m m u n o h i s t o c h e m i s t r y
shows CD99 positivity (Figure 3). Molecular techniques
include FISH analysis revealing EWS gene rearrangements,
including the t(11;22)(q24;q12) translocation resulting in
the EWS-FLI-1 fusion gene, which may also be detected by
PCR (Figure 4). Other translocations include t(21;22) which
result in the EWS-ERG gene fusion, and occur in 10% of
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Figure 2: Kaplan Meier plotof disease-freesurvivalin patientswith
nonmetastatic disease.
(a)
(b)
Figure 3: Histopathology of a nephrectomy specimen: haema-
toxylin and eosin stain, showing tumor composed of sheets of
small round cells with uniform round nuclei and scanty cytoplasm
(×200).Immunohistochemistryshowing diﬀuse membranous pos-
itivity of cells for CD99 (×400).
Ewing’stumors,thoughtheincidenceincasesofextraskeletal
Ewing’s tumors is not known.
There remains some uncertainty regarding the diﬀer-
entiation between Ewing’s sarcoma and PNET, due to
the overlapping pathologic and molecular ﬁndings [10].
However, in practice all Ewing’s family tumors are treated
in the same fashion using a combination of local therapy
and aggressive combination chemotherapy. A signiﬁcant4 Sarcoma
Table 1: Treatment and outcome in the seven patients with primary renal Ewing’s sarcoma.
(a) Patients without metastatic disease at presentation
Age in
years
Year of
diagnosis
Sex
Side of
renal
primary
Radical
nephrec-
tomy
chemotherapy Site of relapse
Disease-free
interval in
months
Status at last
follow up
Survival in
months
50 1993 Male Left Yes 4 VID/2 IE No relapse 149.7 Alive (no
disease) 149.7
34 2000 Male Right Yes 3 CVD/3 EP Lung 55.4 Alive (stable
disease) 107.4
57 2007 Female Left Yes 1 VAC Liver, spleen 5.3
Died
(progressive
disease)
6.5
43 2007 Male Left Yes 4MVAC >
2VIDE > 3VAD Bone 5.1 Alive (stable
disease) 15.6
(b) Patients with metastatic disease at presentation
Age in
years
Year of
diagnosis
Sex
Side of
renal
primary
Radical
nephrec-
tomy
Metastatic site at
presentation chemotherapy
Time to
disease
progression
in months
Status at last
follow up
Survival in
months
35 1997 Female Left No Liver, node 3 PD/3ID 24
Died
(progressive
disease)
62.8
32 1999 Female Right No Liver, node Etoposide 0
Died
(progressive
disease)
26.5
50 2007 Male Left No Liver, adrenal 4VIDE > 6VAC 12
Died
(progressive
disease)
13.1
Abbreviations: V: vincristine (vinblastine in MVAC), P: cisplatin, I: ifosfamide, D: doxorubicin, E: etoposide, A: actinomycin D (doxorubicin in IVAD).
Split signals
Normal fusion signal
EWSR1 “break-apart”probe”
EWSR1 probe located at 22q12 
Figure 4: FISH analysis using Vysis LSI EWSR1 Dual Color
Break Apart Rearrangement Probe for 22q12, showing EWS gene
rearrangement EWSR1 “break-apart” probe EWSR1 probe located
at 22q12 split signalsnormal fusion signal.
proportion of our patients presented with metastatic disease
or developed metastatic disease in spite of adjuvant treat-
ment, and the overall prognosis was poor. Previous studies
of extraskeletal Ewing’s sarcoma suggest that nonskeletal
primarymaybeanunfavourablepredictorforsurvival,other
adverse predictors of survival being metastasis at diagnosis,
older age, incomplete resection, and inadequate response to
chemotherapy [2, 6, 11, 12]. A comparison of the outcome
of renal Ewing’s tumors, reported from series in children
and those in adults, suggest a poorer prognosis in the latter
group. In our study, two of the four patients with primary
disease progressed while on adjuvant chemotherapy, with
liver and bone metastasis, while none of the patients with
metastatic disease at presentation had a durable response
to chemotherapy and all had a short survival. The dismal
outcome of patients with metastatic disease at diagnosis has
been shown in all the previous reported studies [8, 13, 14].
An interesting ﬁnding in our series in comparison to the
previous reports is the preponderance of liver metastasis. In
the series by Thyavihally et al., Jiminez et al., and Rodriguez-
Galindo et al., the common site of distant metastasis was the
lungs, with the liver being the site of metastasis in only one
patient each in these studies [8, 13, 14].
Complete surgery, that is, radical nephrectomy is imper-
ative for the long-term survival of patients with renal Ewing’s
sarcoma [8] .T h ec o m m o ns e q u e n c ef o l l o w e di no u rp a t i e n t s
was radical nephrectomy followed by adjuvant chemother-
apy and in one case postoperative radiotherapy [8]. Ewing’sSarcoma 5
sarcomas are treated with combination chemotherapy,
eﬀective agents being vincristine, doxorubicin, ifosfamide,
etoposide, actinomycin D, and cyclophosphamide. Studies
appear to show that the addition of ifosfamide and etopo-
side to doxorubicin-containing regimens confers a survival
advantage in patients with nonmetastatic disease [15]. The
sequence of initial systemic chemotherapy followed by local
treatment, similar to that practised in extraskeletal Ewing’s
sarcoma from other primary sites, may not be feasible
in these patients owing to the diﬃculty of making the
diagnosis preoperatively. Two of our patients progressed
through chemotherapy with the development of metastatic
disease, and only one patient in the whole series is alive and
disease free. High-dose chemotherapy remains experimental
but may be an option in these patients with locally advanced
disease [4, 16].
8. Conclusion
Primary renal Ewing’s sarcoma in adults is an aggressive
tumor with a high risk of metastatic disease, a common
site being the liver. Aggressive treatment with radical
nephrectomy and adjuvant combination chemotherapy is
recommended, in line with the management of Ewing’s
family tumors at other sites, but in spite of multimodality
treatment the outlook remains poor.
Abbreviations
ES: Ewing’s sarcoma
PNET: Primitive neurectodermal tumor
Hb: Haemoglobin
VAC: Vincristine, ActinomycinD, Cyclophosphamide
VIDE: Vincristine, Ifosfamide, Adriamycin, Etoposide
MVAC: Methotrexate, vinblastine, adriamycin
(doxorubicin), cisplatin
FISH: Fluorescent in-situ hybridisation
PCR: Polymerase chain reaction
CT: Computerised tomography
Gy: Gray.
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